Has Richard Comstock, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,559 in general payments to Richard Comstock, MD across 192 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Comstock, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Comstock, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Comstock, MD

Otolaryngology · Alexandria, VANPI 1962663732

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Sanofi at 25.7% of the total. 2025 is the largest year on record at $1,061, 7.7 times the $138 reported in 2019.

$4,559in general payments, 2019–2025

Across 192 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$1K
Regeneron Healthcare Solutions, Inc.$736
GSK$411
Takeda Pharmaceuticals U.S.A., Inc.$344
Medtronic$239
Pfizer$181
plus $1K from 23 others

What the payments were for

Food & beverage$4,559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	47	$1,170
Regeneron Healthcare Solutions, Inc.	31	$736
GSK	25	$411
Takeda Pharmaceuticals U.S.A., Inc.	14	$344
Medtronic	2	$239
Pfizer	10	$181
Lundbeck LLC	6	$157
Alk-abello, Inc	8	$143
Biocryst US Sales Co., LLC	4	$131
Novartis	6	$130
Aerin Medical Inc.	6	$124
AbbVie	4	$124
Optinose US, Inc.	7	$122
Acclarent, Inc	2	$112
Greer Laboratories, Inc.	3	$77
Stryker	2	$57
Supernus Pharmaceuticals, Inc.	2	$45
Merck	2	$33
Integra Lifesciences Corporation	1	$31
Genentech USA, Inc.	1	$25
Intersect ENT, Inc.	1	$21
Grifols USA, LLC	1	$20
Johnson & Johnson	1	$20
Davol Inc.	1	$20
Vertex	1	$19
Hikma Pharmaceuticals USA	1	$18
Smith+Nephew	1	$17
Kowa Pharmaceuticals America, Inc.	1	$16
Olympus America Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PTEYE PARATHYROID DETECTION SYSTEM$196
DUPIXENT$118

How this compares

$4,559 in reported general payments places this provider in the 80th percentile of 241 otolaryngology providers in Virginia.

See all otolaryngology providers in Virginia →

Medicare billing

Part B allowed, 2024

$125,725

Medicare patients

510

Services billed

1,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	115	$3,551
Ofloxacin	31	$984
Mometasone Furoate	18	$258
Fluticasone Propionate	15	$212
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	21	$193
Methylprednisolone	20	$151
Mupirocin	12	$116
Pantoprazole Sodium	26	$109

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Alexandria

Stanley VoigtAlexandria$6K
Ravi SwamyAlexandria$4K
Jennifer LiangAlexandria$4K
Laurence OhalloranAnnandale$2.9M
Joseph HanNorfolk$1.8M
Ryan NordRichmond$454K
Paul LenkowskiRoanoke$282K
Nipun ChhabraLeesburg$178K
Kent LamNorfolk$127K
Spencer PayneCharlottesville$45K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →